Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

November 30, 2026

Study Completion Date

June 28, 2027

Conditions
Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
Interventions
BIOLOGICAL

Tumor associated antigen lymphocytes (TAA-T)

TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).

Trial Locations (2)

20010

RECRUITING

Childrens National Medical Center, Washington D.C.

21287

RECRUITING

Tania Jain, MD, Baltimore

All Listed Sponsors
collaborator

Children's National Research Institute

OTHER

collaborator

Johns Hopkins University

OTHER

lead

Catherine Bollard

OTHER